Biotron

Clinical-stage Antiviral Pharmaceuticalsbiotron.com.au

Biotron Limited is an Australian, ASX-listed clinical-stage biotechnology company developing small-molecule antivirals that target viral viroporin proteins, with lead asset BIT225 in Phase 2 for HIV-1 and Hepatitis C, and additional programs against SARS-CoV-2 and Hepatitis B.

Company typePublic
Founded2000
HeadquartersBalwyn North, Australia
Headcount51–100
GTM typeB2B
OfferingHardware or Manufacturing

What Biotron does

Biotron Limited (ASX: BIT) is an Australian clinical-stage biotechnology company founded in 1999/2000 and headquartered in Balwyn North (with an operational base described in marketing materials as Sydney, NSW). The company is developing a proprietary class of small-molecule therapeutics that inhibit viral-encoded viroporin proteins, a mechanism intended to suppress replication of established and emerging viruses. Its lead clinical asset, BIT225, is in Phase 2 development for HIV-1 and Hepatitis C virus, with a differentiated claim that it inhibits HIV-1 replication in macrophage reservoir cells and could contribute to HIV-1 eradication when combined with existing antiretroviral regimens. During 2020 the company extended BIT225 into SARS-CoV-2 and reported substantial, clinically meaningful antiviral efficacy in early-stage studies, accelerating its clinical, regulatory and licensing pathway for the COVID-19 indication. A broader preclinical pipeline covers additional viral targets including Hepatitis B.

The business is pre-revenue with no commercial products; Biotron's go-to-market is centred on progressing clinical assets toward licensing or partnership transactions rather than direct sales, supported by an investor-relations stack of ASX announcements, investor webinars, corporate presentations and email newsletters. Revenue is therefore a function of future milestone payments, licensing economics, or strategic transactions rather than recurring product sales. The company has historically been funded through a mix of equity capital raisings and Australian government grants (most notably a $1.7 million Start grant in 2014 for HIV/AIDS clinical development). In late 2025 Biotron completed its first disclosed M&A transaction — the acquisition of Sedarex Limited, announced October 2025 and completed December 2025 — alongside a $2.5 million capital raise, signalling a modest broadening of the operating footprint beyond the single-asset BIT225 platform. Approximately 51-100 employees support ongoing laboratory, clinical and corporate activities.

Biotron firmographics

Firmographics

Name: Biotron
Legal name: Biotron Limited
Website: https://biotron.com.au
Company type: Public
Founded year: 2000
Operating status: Operating
Headcount range: 51–100 employees
Short description: Biotron Limited is an Australian, ASX-listed clinical-stage biotechnology company developing small-molecule antivirals that target viral viroporin proteins, with lead asset BIT225 in Phase 2 for HIV-1 and Hepatitis C, and additional programs against SARS-CoV-2 and Hepatitis B.
Ownership category
akta.pro rank

Biotron industry classification

Industry

Product category: Clinical-stage Antiviral Pharmaceuticals
NAICS: Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC: Pharmaceutical Preparations (2834)
akta.pro primary industry: Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

Keywords

Antiviral therapeutics
HIV-1 treatment
Hepatitis C therapy
Viroporin inhibitors
Clinical-stage biopharmaceuticals

Where Biotron is headquartered

Location

Headquarters

HQ city: Balwyn North
HQ country: Australia
HQ region: Oceania

Markets served

Biotron business model

Business model

GTM type: B2B
Offering type: Hardware or Manufacturing
Cost components: Technology or R&D, Personnel, Operations

Marketing channels6 records

Biotron product offering

Product offering

Core offering

Biotron Limited is a clinical-stage Australian biotechnology company developing a proprietary class of small molecule therapeutics that target viral-encoded viroporin proteins. Its lead compound, BIT225, is in Phase 2 development for HIV-1 and Hepatitis C virus infections, with demonstrated activity against SARS-CoV-2, and the company maintains a preclinical pipeline targeting a broad range of viral diseases including Hepatitis B.

Product overview

Biotron is developing a new class of antiviral therapies focused on small molecule therapeutics that target viral-encoded viroporin proteins. The company's core product is BIT225, which is in Phase 2 development for HIV-1 and HCV, with activity also demonstrated against SARS-CoV-2. The company maintains a robust preclinical pipeline of compounds targeting a broad range of viral diseases including Hepatitis B.

Differentiator

Problem solved

Functional benefit

Products and services

BIT225 Small molecule therapeutic compound in Phase 2 clinical development for the treatment of HIV-1 and Hepatitis C virus (HCV) infections. BIT225 inhibits HIV-1 replication in macrophage reservoir cells, offering potential, when combined with other anti-retroviral compounds, to eradicate HIV-1. It has also demonstrated substantial and clinically meaningful efficacy against SARS-CoV-2 in early-stage research studies.
Preclinical Antiviral Pipeline Portfolio of preclinical small molecule compounds targeting viral-encoded viroporin proteins across a range of established and emerging viral diseases with significant health and economic burden.

Companies that use Biotron

Customer profile

Segments1 record

Ideal customer profiles2 records

Biotron technology and API

Technology

Technology focussed Yes

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Biotron partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights5 records

Biotron competitors and assessment

Company assessment

Broad incumbents

AbbVie: Major pharmaceutical company with HCV franchise (Mavyret) and infectious disease presence. Comparable for HCV therapeutic development, global commercialization capabilities, and combined antiviral pipeline scale.
GSK: Global pharmaceutical company with significant HIV business through its ViiV Healthcare majority ownership. Comparable for HIV therapeutics and global commercialization scale relevant to BIT225's commercial pathway.
Gilead Sciences: Global leader in HIV (Biktarvy, Descovy) and HCV cure therapies (Sovaldi, Harvoni). Comparable as both HIV and HCV therapeutic developer with overlapping disease targets and global commercialization scale.
Regeneron Pharmaceuticals: Major biotech developing antibody-based antiviral therapies including the REGN-COV2 COVID-19 antibody cocktail. Comparable for infectious disease therapeutic development, particularly for SARS-CoV-2, with broader platform reach.
Merck & Co. Major pharmaceutical company with HCV franchise (Zepatier) and significant antiviral R&D. Comparable as a leading infectious disease pharmaceutical developer competing in HCV and the broader antiviral space.
Shionogi: Japanese pharmaceutical company with a strong antiviral franchise including Xocova (ensitrelvir) for COVID-19. Comparable for small-molecule antiviral development targeting similar infectious diseases, particularly SARS-CoV-2.

Direct peers

Atea Pharmaceuticals: Clinical-stage biotech developing oral antiviral therapies for serious viral infections including HCV, RSV, and COVID-19. Closely comparable as a small-cap antiviral developer with similar direct-acting antiviral approach and overlapping indications.
ViiV Healthcare: GSK-majority-owned specialist HIV company focused exclusively on HIV treatment and prevention. Directly comparable as an HIV-focused antiviral developer targeting the same patient population as BIT225.
Vir Biotechnology: Clinical-stage immunology company developing antiviral therapies for serious infectious diseases including HIV, hepatitis B, and influenza. Comparable as a focused antiviral biotech with similar therapeutic targets and clinical-stage assets.

Emerging players

Brii Biosciences: Clinical-stage biotech developing therapeutics for infectious diseases including COVID-19 and hepatitis B. Comparable as an emerging antiviral developer targeting overlapping indications (SARS-CoV-2, HBV) with similar small-molecule focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights6 records

Customer concentration

Biotron financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biotron leadership team

Management profile

Number of profiles

Biotron subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Biotron funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biotron M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biotron

What does Biotron do?

Is Biotron a public or private company?

Biotron is a public company. It is classified as public and is currently operating.

When was Biotron founded?

Biotron was founded in 2000. It employs 51 to 100 people.

Where is Biotron based?

Biotron is headquartered in Balwyn North, Australia, in the Oceania region.

Who are Biotron's main competitors?

Broad incumbents on record are AbbVie, GSK, Gilead Sciences, Regeneron Pharmaceuticals, Merck & Co. and Shionogi. Direct peers are Atea Pharmaceuticals, ViiV Healthcare and Vir Biotechnology. Brii Biosciences is listed as an emerging player.

Does Biotron have an API?

No public API is recorded for Biotron.

What industry is Biotron in?

Biotron's product category is Clinical-stage Antiviral Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.